Atrial Fibrillation (AFib) clinical trials in North Carolina
17 active Atrial Fibrillation (AFib) trials with a site in North Carolina. Describe your situation to see which ones look like a fit.
- The Fourth Left Atrial Appendage Occlusion Study
- A Study of Assessment on Safety and Effectiveness of BWI Pulsed Field Ablation With OMNYPULSE Catheter for the Treatment of Paroxysmal Atrial Fibrillation (PAF)
- Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
- A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation
- A Study of VARIPULSE Pulsed Field Ablation (PFA) Catheter and FARAWAVE PFA Catheter in the Treatment of Participants With Persistent Atrial Fibrillation
- Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
- The CONFORM Pivotal Trial
- Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
- The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
- Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
- Direct Comparison of Cardiac CT With TEE to Evaluate Watchman FLX LAA Occluder Device Characteristics
- PULSED AF Post-Approval Study
- Tracking Results of Ablations to Combat AF Registry Generation 2
- Intra-abdominal Pressure (IAP) During PFA Treatment of A-fib/ A-Flutter
- A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation
- Shared Decision Making to Address Racial Disparities in Oral Anticoagulation in NVAF
- A Registry Based Collaborative to Measure Efficiency, Effectiveness, and Safety of Farapulse PFA Technology for AF
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.